PRESS RELEASE We are happy to announce that we have received consent from the U.

PRESS RELEASE We are happy to announce that we have received consent from the U.S. Government Trade Commission for our acquisition of the Habitrol® brand, an over-the-counter nicotine replacement therapy transdermal patch from Novartis Customer Health Inc. The Habitrol® patch is intended for make use of by habitual smokers to help with reducing withdrawal symptoms, including nicotine craving, connected with quitting smoking. The patch gradually delivers controlled levels of nicotine through the physical body that are lower than the amount in cigarettes.Survival prices for many cancers are poorer in economically developing countries than in developed countries largely due to lack of availability of early detection and treatment solutions. For example, overall five-year childhood tumor survival rates are around 75 % in Europe and North America, in comparison to three-year survival prices of just 48 to 62 % in Central American countries. Particular Section: The Tobacco Epidemic The publication carries a particular section on tobacco’s raising toll. An estimated five million people world-wide died from tobacco use in the year 2000. Of these, about 30 % resulted from cancer, with 850,000 deaths from lung cancer alone. Overall, tobacco was responsible for about 100 million deaths around the world during the 20th century, in fact it is projected to kill a lot more than 1 billion people in the 21st hundred years, with the great majority of these deaths happening in developing countries.